(NASDAQ: STLN) Starling Oncology's forecast annual revenue growth rate of 23.83% is forecast to beat the US Medical Care Facilities industry's average forecast revenue growth rate of 4.12%, and it is also forecast to beat the US market's average forecast revenue growth rate of 15.28%.
Starling Oncology's revenue in 2026 is $587,244,000.On average, 7 Wall Street analysts forecast STLN's revenue for 2026 to be $68,619,101,068, with the lowest STLN revenue forecast at $64,631,123,488, and the highest STLN revenue forecast at $71,697,986,903. On average, 6 Wall Street analysts forecast STLN's revenue for 2027 to be $89,309,091,575, with the lowest STLN revenue forecast at $81,470,723,170, and the highest STLN revenue forecast at $95,026,585,626.
In 2028, STLN is forecast to generate $118,426,525,630 in revenue, with the lowest revenue forecast at $113,840,300,455 and the highest revenue forecast at $121,891,673,540.